Iterum Therapeutics Stock (NASDAQ:ITRM)
Previous Close
$0.71
52W Range
$0.61 - $3.02
50D Avg
$0.80
200D Avg
$1.24
Market Cap
$30.48M
Avg Vol (3M)
$826.38K
Beta
3.04
Div Yield
-
ITRM Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.